Copaxone repairs nerve tissue in multiple sclerosis patients, said Teva Pharmaceutical Industries Ltd. in reporting the results of a 12-month MRI study on the evolution of multiple sclerosis lesions. The study was published in the January issue of "Frontiers in Bioscience".
“These data indicate that treatment with Copaxone resulted in a measureable amount of tissue repair in study patients,” said the lead research Dr. Robert Zivadinov, Director of the Buffalo Neuroimaging Analysis Center at the University at Buffalo. “The observed increases in magnetization transfer ratio (MTR) point to a potential for remyelination.
Overall, these findings contribute to the vast body of research that supports the long-term efficacy and safety of the therapy."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1767